N.V. Rukosueva - Assistent, Lomonosov Moscow State University of Fine Chemical Technologes, Moscow. E-mail: nata1i@list.ru
A.P. Kaplun - Dr.Sc. (Chem.), Professor, Lomonosov Moscow State University of Fine Chemical Technologes, Moscow. E-mail: alexander.p.kaplun@gmail.com
N.A. Zigangirova - Dr.Sc. (Biol.), Professor, Gamaleya Research Institute for Epidemiology and Microbiology, Moscow. E-mail: zigangirova@mail.ru
L.N. Kapotina - Dr. Sc. (Eng.), Gamaleya Research Institute for Epidemiology and Microbiology, Moscow. E-mail: lidiya.kapotina57@mail.ru
V.I. Shvets - Dr. Sc. (Chem.), Academician RAS, Professor, Lomonosov Moscow State University of Fine Chemical Technologes. E-mail: bt@mitht.ru

Currently, the search for new small molecule therapeutic agents and the creation of genetically engineered effectors holds leading positions in the pharmaceutical and biotechnology. Moreover, in recent years, particular attention is paid to substances of natural origin, in particular polyphenols. Such interest in this group of compounds is probably due to a huge range of therapeutic activities. In particular, resveratrol (RSV) (a polyphenol founded in the skins of various plants), has a number of biological activities, including antichlamydia (according to data of the laboratory clamydioses Gamaleya Institute of Epidemiology and Microbiology). It makes this compound very promising agent for the treatment of chronic forms of chlamydiosis. However, resveratrol is practically insoluble in water and is toxic at concentrations greater than 100 mkM. In this paper these problems are solved by encapsulation of resveratrol in liposomes of soya phosphatidylcholine. The obtaining aqueous liposomal dispersion contains the active substance in a concentration of 0.56 mg / ml (2.45 mM), (which is 12 times higher than the solubility of resveratrol) on average 35% less toxic than sodium resveratrol concentrations in the range of 75-100 mkM ( in vitro). It allows you to extend the range of therapeutically relevant concentrations with 25-50 mM solution for up to 25-100 mkM for liposomal dispersion.

 

1. Kalantari H., Das D. Physiological effects of resveratrol // BioFactors. 2010. V. 36. № 5. P. 401-406.
2. Patel K., Scott E., Brown V., Gescher A., Steward W., Brown K. Clinical trials of resveratrol // Ann. N.Y. Acad. Sci. 2011. V. 1215. P. 161-169.
3. Tome-Carneiro J., Larossa M., Gonzalez-Sarrias A., Tomas-Barberan F., Garcia-Conesa M., Espin J. C. Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence // Current Pharm. Design. 2013. V. 19. P. 6064-6093.
4. Borczov P. Antiapoptozny'e belki - misheni dlya poiska novy'x antixlamidijny'x preparatov / Dissertacziya na soiskanie uchenoj stepeni kandidata mediczinskix nauk. M. 2010.
5. Camon L., Cottart C.-H., Rhayem Y., Nuvent-Antoine V., Djelidi R., Collin F., Beaudeux J.-L., Bonnefont-Rousselot D. Simple spectrophotometric assessment of the trans -/ cis - resveratrol ratio in aqueous solutions // Analyt. Chim. Acta. 2009. V. 634. P. 121-128.
6. Trela B., Waterhouse A. Resveratrol: isomeric molar absorptivities and stability // J. Agric Food Chem. 1996. V. 44. P. 1253-1257.
7. Kristl J., Teskacˇ K., Caddeo C., Abramovic´ Z., Šentjurc M. mprovements of cellular stress response on resveratrol in liposomes // Europ. J. Pharm.Biopharm. 2009. V. 73. P. 253-259.
8. Augustin M.A., Sanguansri L., Lockett T. Nano- and micro-encapsulated systems for enhancing the delivery of resveratrol // Ann. N.Y. Acad. Sci. 2013. V. 1. 290. P. 107-112.
9. Duncan R, Gaspar R. Nanjmedicine(s) under the microscope // Mol. Pharmaceutics. 2011. V. 8. № 6. P. 2101-2141.